Candidates comprise nucleoside analogs linked to small cyclic peptidomimetics.

JPT Peptide Technologies is teaming up with Spain’s IUCT and LEITAT on a collaboration to develop targeted anticancer therapies comprising nucleoside analogs linked to small cyclic peptidomimetics. The partnership will combine JPT’s peptide-based hit identification and hit-to-lead expertise, with IUCT and LEITAT’s capabilities in the synthesis of nucleoside analogues and activity screening.

The ultimate aim is to generate safer and more effective chemotherapeutics by selectively targeting cytotoxic compounds to tumor cells. “IUCT and LEITAT have been successfully working on the development of new therapies against neoplastic diseases for several years,” comments Josep Castells, executive president ad IUCT. “With JPT we have found a reputable and strong partner that complements our own expertise in creating new targeted anticancer compounds.”

IUCT develops products and processes in the fields of drug discovery, drug development and industrial biotech, for licensing out the pharmaceutical and biotech sectors. The firm has expertise in a wide range of therapeutic areas. LEITAT isa private research center developing new technologies for the biomedical, oncology, nanotechnology and biomaterials sectors. The firm has specialized expertise in the discovery, development and in vitro/in vivo characterization of anticancer targets and drug candidates.  

Previous articleGenentech Pays Constellation $95M in Epigenetic Drug Collaboration
Next articlePfizer, Medivation Nix Development of Alzheimer Disease Therapy